New technology enhances pharmaceutical manufacturing capabilities for improved drug delivery.
- Codis invests in GEA PSD4 spray dryer technology.
- The investment aims to improve the manufacturing of amorphous solid dispersions.
- This technology enhances drug delivery mechanisms in pharmaceuticals.
Codis has made a significant advancement in pharmaceutical manufacturing by investing in a GEA PSD4 solvent spray dryer. This new technology is set to enhance the production of amorphous solid dispersions, which play a crucial role in improving drug delivery. Amorphous solid dispersions are known for their ability to increase the solubility of poorly soluble drugs, thereby enhancing patient outcomes.
The GEA PSD4 spray dryer allows for efficient and scalable production of these formulations. By employing this advanced equipment, Codis aims to optimize their manufacturing processes, ultimately leading to better drug availability in the market. This development in drug formulation technology could significantly benefit the pharmaceutical industry, making it easier to develop effective medications.
With the introduction of the GEA PSD4, Codis is positioned to strengthen its capabilities in pharmaceutical formulation. The focus on amorphous solid dispersions aligns with current trends aimed at developing sustainable and more effective drug delivery systems. This investment marks a pivotal step in maintaining competitiveness in the evolving landscape of pharmaceutical manufacturing.
